NCT06427018 Expressions of Ezrin and Pip5k1α Proteins in Airway Smooth Muscle of Asthmatic Patients
| NCT ID | NCT06427018 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Lei-Miao Yin |
| Condition | Asthma |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2024-05-28 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2024-05-28 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Asthma, a prevalent chronic respiratory affliction, significantly impinges upon the quality of life for affected individuals. Timely and appropriate diagnostic measures, coupled with efficacious therapeutic interventions, are paramount in mitigating exacerbations of symptoms and enhancing the life quality of patients. Ezrin plays an important role in maintaining cell morphology, cell migration, cell adhesion and polarisation, but Ezrin expression in airway smooth muscle remains unclear. Pip5k1α is an important kinase involved in intracellular phosphatidylinositol signalling pathways that may be involved in smooth muscle contraction and diastole. Therefore, further studies are necessary to elucidate the changes of Ezrin and Pip5k1α in patients with asthma to provide a basis for investigating alternative treatments for asthma.
Eligibility Criteria
Inclusion Criteria: * Lung tissue samples; * The samples come from patients aged 18-70 years old, regardless of gender, who underwent lung tissue sampling for surgical indications during treatment; * Paraffin sections of lung tissue from patients diagnosed with bronchial asthma, including tracheal smooth muscle; * Paraffin sections of lung tissue from non-asthma patients, including tracheal smooth muscle. Exclusion Criteria: * Paraffin sections of lung tissue from patients who have been diagnosed with COPD; * Other situations where the researcher deems it inappropriate to participate in this study.
Contact & Investigator
Lei-Miao Yin, MD
STUDY DIRECTOR
Yueyang Hospital, Shanghai University of Traditional Chinese medicine
Frequently Asked Questions
Who can join the NCT06427018 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06427018 currently recruiting?
Yes, NCT06427018 is actively recruiting participants. Contact the research team at collegeylm@shutcm.edu.cn for enrollment information.
Where is the NCT06427018 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06427018 clinical trial?
NCT06427018 is sponsored by Lei-Miao Yin. The principal investigator is Lei-Miao Yin, MD at Yueyang Hospital, Shanghai University of Traditional Chinese medicine. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.